Juan Carlos Jaen
Co- Founder & PresidentDr. Juan Carlos Jaen, Ph.D., is Member of Advisory Board of Breakpoint Therapeutics GmbH. Dr. Jaen co-founded Arcus Biosciences, Inc. in 2015 and has been its President since May 2015 also served as its Chief Scientific Officer. Dr. Jaen served as Member of Scientific Advisory Board of Eikon Therapeutics, Inc. until September 2022. Dr. Jaen serves as a Director at Hexagon Bio, Inc. He serves as Director of Shasqi, Inc. since October 2020. He served as Director at PACT Pharma, Inc. until 2022. He serves as Director of Shasqi, Inc. Dr. Jaen has been engaged in all aspects of drug discovery and development for years. Prior to Arcus, he co-founded Flexus Biosciences in 2013. Prior to Flexus, Dr. Jaen held the position of Chief Scientific Officer and Senior Vice President of Drug Discovery at ChemoCentryx from 2007 to September 2013. During his tenure there (2007-2013), he led the discovery and progression into the clinic of 8 novel drug candidates in the immunology space. As corporate officer, he participated in multiple corporate collaborations and financing events, including the company’s IPO in February 2012. From 1996 to 2004, he held positions as Director of Medicinal Chemistry and Vice President of Chemistry at Tularik, Incorporated. He also served as the President of PACT Pharma, Inc. a biopharmaceutical company, from November 2016 until December 2017. He briefly in April 2015 as the President of FLX Bio, Incorporated. Previously, Dr. Jaen served as the President and Head of Research and Development at Flexus Biosciences, Incorporated from October 2013 to April 2015. Prior to that, Dr. Jaen held several positions in drug discovery and program management, from 1983 to 1996, at the Parke-Davis Pharmaceutical Research division of Warner-Lambert Company, a pharmaceutical company. He serves on the board of directors of R2M Pharma, Inc. PACT Pharma, Inc. Breakpoint Therapeutics GmbH, Hexagon Bio, Inc. Shasqi, Incorporated and the Bella Charitable Foundation. From 1996 to 2006, he held various scientific management positions at Tularik (responsible for about 100 scientists in Medicinal and Computational Chemistry, as well as Structural Biology) and then Amgen Inc. (after its acquisition of Tularik in 2004), most recently as Vice President of Chemistry from 2004 to 2006. From 1983 to 1996, Dr. Jaen held various positions at Parke-Davis/Warner-Lambert, prior to its acquisition by Pfizer. He had been Director of Arcus Biosciences, Inc. since April 2015 until January 2024. He has co-authored over 100 scientific papers and is an inventor on 48 issued U.S. patents. He has been responsible for the advancement of over 20 novel molecules into clinical development for diseases including cancer, Alzheimer’s, Crohn’s, RA, diabetes and diabetic nephropathy, psoriasis, asthma and vasculitis, among others. He earned a Ph.D. degree in Organic Chemistry from the University of Michigan in 1983. He holds a B.S. and M.S. in Chemistry from the Universidad Complutense de Madrid in 1980.
Positions
- Company NameArcus Biosciences, Inc.Stock CodeRCUSPositionCo- Founder & PresidentColleagues
- TJTerry J. RosenCo-Founder, Chairman & CEO
- RCRobert C. GoeltzPrincipal Financial Officer & CFO
- RARichard A. MarkusChief Medical Officer
- KCK. Christopher GarciaCo-Founder & Member of Scientific Advisory Board
- KEKathryn E. FalbergIndependent Director
- YKYasunori KanekoLead Independent Director
- JAJeffrey A. BluestoneChairman of Scientific Advisory Board
